W
WaferGen Biosystems
Life science company offering genomic tools for targeted resequencing, genotyping and expression analysis
About WaferGen Biosystems
WaferGen, now part of Takara Bio USA, Inc., specializes in providing advanced genomic technology solutions for single-cell analysis and clinical research. The company offers a range of innovative platforms, including the ICELL8® Single-Cell System, which isolates thousands of single cells for various analysis methods such as next-generation sequencing. This system can handle up to 1,800 single cells on a single chip, making it suitable for analyzing cells from solid tumors, brain tissues, pulmonary airway cells, and multiple cell lines.
The SmartChip™ platform is designed for profiling and validating molecular biomarkers and can perform massively parallel singleplex PCR for one-step NGS library preparation in clinical applications. Additionally, the Apollo™ 324 system processes DNA and RNA from clinical samples into NGS-ready libraries. These technologies serve the life sciences, pharmaceutical, and clinical laboratory industries, providing powerful tools for biological analysis at both the molecular and single-cell levels.
WaferGen's business model focuses on selling these specialized systems to research institutions, pharmaceutical companies, and clinical laboratories. Revenue is generated through the sale of these platforms and associated consumables, as well as through service contracts and support agreements. The company operates in a niche market that demands high precision and reliability, catering to clients who require advanced genomic analysis capabilities.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2002
- Headquarters
- Fremont, United States
- Listing
- IPO 2007
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 58.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2016 | $50M | $50M | Undisclosed | — |
| GROWTH EQUITY VC✓Equity / VC | Aug 2013 | $15M | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $7.2M | 0% |
| 2025 | $7.2M | 0% |
| 2024 | $7.2M | 0% |
| 2023 | $7.2M | 0% |
| 2022 | $7.2M | 0% |
| 2021 | $7.2M | 0% |
| 2020 | $7.2M | — |
Growth signals
Latest recorded traffic for WaferGen Biosystems is 240 monthly website visits. WaferGen Biosystems's team declined 19.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Great Point Partners- MNMerlin Nexus
Deerfield
Other known investors1 additional known investor
Technoport
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about WaferGen Biosystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See WaferGen Biosystems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.